Brief: Ikena Oncology Receives FDA Fast Track Designation For Novel AHR Antagonist Ik-175 In Combination With Nivolumab To Treat Urothelial Carcinoma

ImageneBio

06/03/2023 13:18

March 6 (Reuters) - Ikena Oncology Inc  IKNA.O :
    * IKENA ONCOLOGY RECEIVES FDA FAST TRACK DESIGNATION FOR
NOVEL AHR
ANTAGONIST IK-175 IN COMBINATION WITH NIVOLUMAB TO TREAT
UROTHELIAL CARCINOMA
    * IKENA ONCOLOGY-IK-175 PROGRAM BEING DEVELOPED IN
COLLABORATION
WITH BRISTOL MYERS SQUIBB,HAVE OPTION TO EXCLUSIVELY LICENSE
PROGRAM THROUGH EARLY 2024

Source text for Eikon:  ID:nGNX62rb17 
Further company coverage:  IKNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))